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cis-Diamminedichloroplatinum(II) (cisplatin, DDP) is a cornerstone of anticancer therapy and
has become one of the most widely used drugs for the treatment of various epithelial
malignancies. The cytotoxicity of cisplatin is mainly based upon its affinity to adjacent
guanines in nucleic acids, resulting in the formation of 1,2-intrastrand adducts. In this study
the gas-phase dissociation of DNA- and RNA-cisplatin adducts is investigated by electrospray
ionization (ESI) tandem mass spectrometry (MS/MS). The fundamental mechanistic aspects of
fragmentation are elucidated to provide the basis for the tandem mass spectrometric
determination of binding motifs and binding sites of this important anticancer drug. It is
shown that the binding of cisplatin to vicinal guanines drastically alters the gas-phase
fragmentation behavior of oligonucleotides. The 3=-C–O bond adjacent to the GG base pair is
preferentially cleaved, leading to extensive formation of the corresponding w-ion. This
observation was even made for oligoribonucleotides, which usually tend to form c- and y-ions
under CID conditions. The absence of complementary ions of equal abundance indicates that
oligonucleotide-cisplatin adducts are following more than one dissociation pathway in the
gas-phase. Several mechanisms that explain the increased cleavage of the 3=-C–O bond and the
lack of the complementary a-ion are proposed. Results of additional MS/MS experiments on
methylphosphonate-oligodeoxynucleotides confirm the proposed mechanisms. (J Am Soc
Mass Spectrom 2009, 20, 792–804) © 2009 Published by Elsevier Inc. on behalf of American
Society for Mass Spectrometrycis-Diamminedichloroplatinum(II) (cisplatin, DDP)revolutionized anticancer therapy like no otherchemotherapeutic agent. The incidental discovery
of its cytotoxic properties by Rosenberg et al. in 1965
and Hill’s subsequent clinical tests in the 19s were a
breakthrough in oncology [1, 2]. It marked the start of
an effective cancer treatment by enhancing the chances
of a successful cure of various epithelial malignancies
such as lung, head, neck, ovarian, bladder, and testicu-
lar cancer [3]. However, due to severe side effects,
evolving resistance of cancer cells to cisplatin during
treatment, and the problem that cisplatin cannot combat
all types of cancer successfully, the development of
potent platinum based alternatives such as carboplatin
and oxaliplatin has become an important issue in cancer
research [2, 4–6]. From the very beginning, it was
crucial to gain deeper insight into the pathway cisplatin
follows in vivo and to determine its principal cellular
targets as well as the mode of interaction. So far,
experiments revealed that DDP reacts preferentially
with DNA, but that other substrates, such as RNA,
phospholipids and phosphatidylserine in membranes,
as well as proteins and peptides, can serve as targets as
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doi:10.1016/j.jasms.2008.12.018well, even though to a lesser extent [7–18]. The cellular
uptake is believed to be controlled by passive diffusion
through the cell membrane, which is feasible for a
neutral molecule such as cisplatin [17, 19, 20]. The
biologically active substrate is formed in vivo after
entering the cell, as the relatively high chloride ion
concentration in blood prevents cisplatin from prior
hydrolysis. However, the chloride concentration in the
cytoplasm is far lower and thus, the positively charged
monoaqua-complex [Pt(NH3)2Cl(H2O)]
 is formed, an
electrophile that is reactive against any nucleophile
present in the cell [3].
The N7 position of guanine as the most electron rich
region of all nucleobases represents the most favored
binding site of cisplatin, being preferred over N7 of
adenine and N3 of cytosine [21]. After the monofunc-
tional adduct is established, hydrolysis of the second
chloride ligand takes place and the final bidentate form
is generated [22, 23]. Fichtinger-Schepman et al. found
that 1,2-intrastrand cross-links of cis-[Pt(NH3)2(GpG)]
constitute 47% to 50% of all adducts, followed by
cis-[Pt(NH3)2(ApG)] accounting for another 23% to 28%.
Furthermore, 1,3-intrastrand cross-links of non-adjacent
guanines as well as interstrand adducts were observed
in 8% to 10% of all digestion products [21]. Additional
studies, including in vivo experiments, confirmed these
results [24–28].
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erably distorted and a bend towards the major groove
and a widening of the minor groove could be observed
[29, 30]. Such structural alteration most likely interferes
with replication and transcription, thus inhibiting DNA
synthesis [31–35]. Particularly, transcription seems to
have greater impact on apoptosis than initially expected
[36–39]. Most publications about cisplatin-oligonucleotide
adducts are focusing on localization of the exact adduct
position within the sequence. Generally, enzymatic
digestion in combination with liquid chromatography
and mass spectrometry has been used [40–43].
MS/MS emerged to an excellent tool for obtaining
sequence information of modified nucleic acids, which
are resistant to degradation by classical methods. The
main advantages of MS/MS are its independence from
specific structural prerequisites of the oligonucleotide
and the high degree of information obtained by a single
experiment consuming minute amounts of sample only.
The technique provides detailed information about pla-
tinated oligonucleotides, especially regarding structural
modifications and cross-linking patterns.
During the past decades, there has been great
progress in the characterization of oligodeoxynucleoti-
des by tandem mass spectrometry. As one of the earlier
soft ionization techniques, fast atom bombardment was
found to be a suitable method to transfer di-, tri-, and
tetra-nucleotides into the gas phase and it has been the
method of choice for the ionization of small nucleic
acids for a long time. Early FAB experiments revealed
the unique dissociation behavior of oligonucleotides
[44–46] and it was found that the deprotonated phos-
phate group plays a major role in the dissociation of
native oligonucleotides [47]. In the 1990s mass spectro-
metric studies using ESI and MALDI further extended
our knowledge on the gas-phase dissociation of DNA
and RNA oligomers. In 1998, Wang et al. [48] proposed
a charge-remote mechanism for the formation of [a 
B]-ions. Evidence supporting such mechanism was sub-
sequently provided by the groups of Hillenkamp and
Gross, based on H/D exchange experiments [49] and
tandem mass spectrometry of methylphosphonate-
modified sequences [50]. The preferred generation of c-
and y-ions upon dissociation of RNA was reported by
Cerny et al. [51] in the 1980s. Later, mechanistic data on
the dissociation of negatively charged oligoribonucleo-
tides was provided by Schürch et al. [52, 53], followed
by a demonstration of RNA decomposition in gas phase
by Andersen et al. in 2006 [54], who examined the
dissociation of positively charged MALDI-generated
tetranucleotides utilizing H/D exchange experiments.
On the other hand, there are only few publications
on tandem mass spectrometry of oligonucleotide-
cisplatin adducts. Initial experiments were carried out
using DDP in conjunction with nucleobases or mono-
nucleosides as well as platinated bis(nucleobase) com-
pounds [55, 56]. The utilization of electron impact
ionization (EI) was quite problematic due to the high
polarity and low vapor pressure of underivatizednucleosides, nucleotides, and oligonucleotides [57, 58].
However, Roos et al. used EI to investigate the interac-
tions of cis- and trans-DDP with nucleoside analogues
such as 1-methylcytosine and 9-methylguanine [56].
They mainly inferred the observed molecular and frag-
ment ions from the corresponding isotopic ratio pat-
terns, which led to some evidence for a preferred
binding site. Furthermore, EI in conjunction with pyrol-
ysis MS was applied to analyze a series of DNA-
cisplatin complexes by Macquet et al. [59]. They ob-
served a considerable change in the abundance of the
C- and G-derived fragment ions after binding of five
cisplatin molecules to 1000 bases of salmon sperm DNA
and consequently, stated that these nucleobases consti-
tute the primary site of interaction. Nine years later,
Claereboudt et al. performed MS/MS experiments of
cisplatin and its higher molecular weight analogues by
using FAB mass spectrometry as well as laser micro-
probe mass spectrometry (LAMMA) [60]. They ob-
tained structurally significant fragment ions for e.g.,
1R,2R-diaminecyclohexane(oxalato)platinum(II) and
diamine(malonato)-platinum(II). In case of cisplatin
they mainly observed sequential loss of the ammine
and chloride ligands.
The first reports on platinated oligonucleotides in
connection with FAB tandem mass spectrometry were
published in 1991 by Martin et al. [61] and in 1992 by
Costello et al. [62]. They found consistently that loss of
NH3 groups from the ligand sphere of platinum is one
of the dominant reaction pathways together with N-
glycosidic bond cleavage. Additionally, Costello et al.
demonstrated that fragments containing platinum as
well as one or both guanines represent a prominent set
of product ions after CID, thus, giving evidence for the
cleavage of the N-glycosidic bond(s). This observation
is in good agreement with a theoretical study by Baik et
al. [63] who have shown that platination as well as
protonation of guanosine (dGuo) drastically reduces
the gas-phase heterolytic bond dissociation energy
(BDE) of the N9–C1= glycosidic bond. They calculated
that the BDE of dGuo(Pt) is almost 80 kcal mol1 less
than the BDE of native dGuo (H  140.9 kcal mol1).
Hence, likely cleavage of the N-glycosidic bond is
selectively promoted when DDP is bound to a nucleo-
base. Furthermore, the authors suggested the formation
of a 5-coordinate platinum as an intermediate species in
the fragmentation process, which the phosphate oxygen
is involved in. Moreover, Martin et al. showed, that
platination generally results in stabilization of the oli-
gonucleotide and a significant decrease of the abun-
dance of fragment ions.
More recent MS/MS studies were performed in
combination with ESI or MALDI to take advantage of
their soft ionization character. Iannitti-Tito et al. [64]
performed ESI-MS/MS experiments on the cisplatin
adduct of CACGTG, confirming the main findings of
Martin et al. and Costello et al. (NH3-loss, N-glycosidic
bond cleavage). In the negative ion mode, though, no
sequence-specific fragmentation could be observed.
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extensive structural information regarding platinum-
containing ions, since platinated fragments are rather
positively than negatively charged. To obtain conclu-
sive sequence information, additional MS/MS experi-
ments of the major product ions generated by colli-
sional activation in the ion source were performed.
A recent tandem mass spectrometric study by Zhang
et al. aimed at the elucidation of three-dimensional
structures of nucleic acids cross-linked by cisplatin [65].
In this case they subjected the platinated dinucleotide
d(GG) to sustained off-resonance irradiation (SORI) in a
FTMS instrument equipped with a nanoESI source.
They found the positively charged [Pt(NH3)G2] ion,
which results from cleavage of both N-glycosidic
bonds, to be the most abundant fragment along with
a1-B1- and [G  Pt]-ions. The initial findings of Costello
et al. and Martin et al. were approved in further studies
by several groups. However, to our knowledge no
fragmentation mechanism of platinated oligonucleo-
tides has been published yet.
In the present study, the gas-phase dissociation of
platinated oligonucleotides and methylphosphonate-
oligodeoxynucleotides has been investigated by electro-
spray ionization tandem mass spectrometry in the neg-
ative ion mode to elucidate the influence of cisplatin on
the fragmentation pathways of oligonucleotides. The
most characteristic fragment ions are discussed and
three dissociation mechanisms, based on the data ob-
tained from methylphosphonate oligonucleotides, are
presented.
Experimental
Oligonucleotides, Chemicals, and Solvents
HPLC purified single stranded (ss) oligodeoxynucleoti-
des (CGGCTT, CCGGTT, CCTGGT, CGTGCT, CCG-
GCTGGTT) were purchased from Microsynth (Balgach,
Switzerland), whereas methylphosphonate-modified
oligodeoxynucleotides were ordered from Eurogentec
S.A. (Seraing, Belgium). Oligoribonucleotides (CGG-
CUU, CCGGUU, CCUGGU) were obtained from Tri-
Link Biotechnologies (San Diego, CA). All oligonucleo-
tides were used without further purification. The oligo-
nucleotide solutions were prepared with concentrations
of 50 pmol/L in water:acetonitrile:triethyl amine (49:
49:2 vol/vol/vol). Acetonitrile was purchased in HPLC
quality from Romil Ltd., Cambridge, UK. Fluka HPLC
quality water (Sigma-Aldrich Chemie GmbH, Buchs,
Switzerland) was used for all solutions.
cis-Diamminedichloroplatinum (II) was purchased
from Sigma-Aldrich Chemical Co. (St. Louis, MO).
After the DDP-solution has been incubated with water
for 24 h at 37 °C to form the reactive diaqua species
[Pt(NH3)2(OH2)2]
, it was mixed with the oligonucleo-
tide in a molar ratio of 1.2 : 1 (120 pmol/L:100
pmol/L) and incubated for another 24 h at 37 °C.
Before mass spectrometric analysis, the reaction mix-ture it was diluted with water to yield a final concen-
tration of 70 pmol/L, approximately.
Mass Spectrometry
All experiments were performed on an Applied Biosys-
tems/MDS SCIEX QSTAR Pulsar hybrid quadrupole
time-of-flight mass spectrometer (SCIEX, Concord, On-
tario, Canada), equipped with a nanoelectrospray ion
source (Proxeon Biosystems, Odense, Denmark). Oligo-
nucleotides were analyzed in the negative ion mode
with a potential of 850 V applied to the nanospray
needle. Nitrogen was used as the curtain gas. Tandem
mass spectrometric experiments were performed with
the precursor ions selected within a window of1.5m/z
units. Collision-induced dissociation was performed
with collision energies of 20 to 30 eV using nitrogen
as the collision gas. Spectra were acquired over a m/z
range from 100 to 2000. Calibration of the instrument
was performed with caesium iodide and taurocholic
acid (Fluka, Buchs, Switzerland). The Applied Biosys-
tems Analyst QS software package was used for data
processing.
Results and Discussion
Binding of Cisplatin to Oligodeoxyribonucleotides
(DNA)
The mass spectra of the platinated 6-mers CGGCTT,
CCGGTT, and CCTGGT provided proof of successful
adduct formation. Triply and quadruply charged ions
were observed most frequently. In some cases the loss
of one or two ammine ligands could be observed, which
is consistent with previous findings. For an unambigu-
ous identification of the platinated precursor the calcu-
lated isotopic distributions were compared with the
experimental results.
Subsequent tandem mass spectrometric experiments
confirmed the preference of cisplatin to form adducts
with adjacent guanines, since platinated fragments
were solely detected if they contain at least one guanine.
Furthermore, loss of one or two NH3 ligands was
observed, which is also in good agreement with former
studies. Moreover, it is striking that after addition of
cisplatin the formation of the w-ion, which is generated
by cleavage of the 3=C–O bond next to the GG base pair,
is considerably enhanced.
As a representative example for all hexanucleotides,
the spectra of platinated and unplatinated CCGGTT,
are shown in Figure 1. Comparison of the two spectra
demonstrates the increase of the w2-ion (m/z 625.09)
abundance compared to the w1-ions (m/z 321.05). This
observation was also made for the other hexanucleoti-
des CGGCTT and CCTGGT, which showed a strong
increase of the w3- and w1-ion abundance, respectively.
(In the following paragraphs, these w-ions, which are
formed by cleavage of the 3=-C–O bond at the 3=-side of
the GG base pair, are referred to as wx-ions). This
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presence of two adjacent or 1,3-vicinal non-terminal
guanines within the nucleotide sequence and has not
been described in literature yet. Our results clearly
point out that the 3=-C–O bond adjacent to vicinal
guanines is particularly affected by the DDP moiety.
To validate the observation of a stringent 3=-C–O
bond cleavage after adjacent guanines, the decamer
CCGGCTGGTT, which is able to bind two cisplatin
moieties, was subjected to CID as well. The results are
summarized in Figure 2 and Table 1. The abundant
w-ions reflect the preferred cleavage of the 3=-C–O
bond. Since the most abundant fragment ions are still
those produced by backbone cleavage after the platina-
tion site (w2, [w6  DDP]), bond dissociation after
platinated vicinal guanines also persists with longer
sequences. For this reason the 3=-C–O phosphate ester
bond stability 3= adjacent to both guanines seems to be
generally influenced by the proximity of cisplatin, irre-
spective of the length of the oligonucleotide.
Among the platinated fragment ions, the [a4 
Pt]-ion (m/z 682.09) represents the most abundant dis-
sociation product in the MS/MS spectrum of the CCG-
GTT-DDP adduct and constitutes the complementary
ion to the w2 fragment (Figure 1). Generally, the [an  x
Pt]-ion (n total number of nucleotides, and x length
of the w fragment ion resulting from cleavage on the
3=-side of the GG base pair) represents the most abun-
dant platinated fragment for all three hexamers. The
fact that no complementary ions of comparable inten-
sity are observed and that a- as well as a-B-ions are
formed, suggests that most probably there are multiple
fragmentation pathways, all leading to wx-ions. The
comparison of platinated and unplatinated fragment
Figure 1. Product ion spectra of unplatinated
abundance is observed after addition of DDP.
Figure 2. The w - and [w  Pt]-ions represent the preferred2 6
cleavage sites of the platinated decamer CCGGCTGGTT.ion intensities must be handled with care, taking into
account the apparently reduced peak intensities of
platinated ions caused by the broader isotopic distribu-
tion and peak splitting due to NH3-loss.
In general, the binding of cisplatin results in a
considerable decrease of the diversity of the product ion
spectra, which is clearly visible in Figure 1. It is unlikely
that this effect is solely provoked by the presence of the
platinum moiety, which holds two positive charges and
hence, excludes short fragments from detection in the
negative ion mode. Since the oligonucleotide sequen-
ces are long enough, most fragments should still be
negatively charged and nevertheless, the a-B-series 5=-
adjacent to the cisplatin adduct could actually be gen-
erated just as normal for CCGGTT and CCTGGT.
The most abundant fragment ions observed upon
CID of the hexadeoxynucleotide-cisplatin adducts are
indicated in Figure 3. Backbone dissociation of all
oligonucleotides was found to be influenced by DDP in
a similar manner. Comparing the product ion spectra of
the uncomplexed oligonucleotides with those of the
platinated species, it is conspicuous that except for the
site of platination, intensive fragmentation is quite
restricted. Only the product ion spectrum of CGGCTT 
DDP deviates from the spectra of the other oligonucle-
otides as it lacks the [a2  Pt] as well as the [a3-G  Pt]
fragment. However, these fragments would be neutral
Table 1. Relative intensities of w-ions generated by CID of
doubly platinated d(CCGGCTGGTT). The w-ions resulting from
cleavage of the 3-C-O bond next to the cisplatior adduct
represent the most abundant fragments.
Fragment Unplatinated 1 Platinated
w1 29.0 0.0
w2 100 0.0
w3 18.3 0.0
w4 0.8 13.4
w5 2.2 45.2
w6 0.2 100
w7 0.0 13.4
w8 0.1 14.4
platinated CCGGTT. An increase of the w2-ionandw9 0.0 0.0
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tection in the negative ion mode. Generally, short
platinum-containing fragments might not be able to
compensate for the positive charges introduced by the
metal ion, thus, resulting in an uncharged or even
positively charged fragment. Principally, backbone dis-
sociation on the 5=-side of GG was found to be signifi-
cantly reduced, whereas cleavage on the 3=-side of the
vicinal guanines was affected less in comparison to the
unplatinated species.
Our observations lead to the conclusion that cisplatin
is promoting the generation of wx-ions of platinated
oligodeoxynucleotides in the gas phase and that frag-
mentation is basically limited to the vicinity of the
GG-cisplatin adduct. In general, the extent of decrease
in peak abundance of platinated fragment ions is af-
fected by the choice of sequence, the charge state of the
Figure 3. Most abundant fragments formed upon CID of plati-
nated CGGCTT, CCGGTT, CCTGGT.
Figure 4. Structures of the [a Pt]-fragment w
in a mass difference of 1 Da.precursor ion, and the overall length of the oligonucle-
otide. When studying the dissociation of short model
compounds in the negative ion mode, the limited num-
ber of phosphate groups might be insufficient to com-
pensate for the two positive charges added by DDP.
Consequently, the decrease in peak abundance is most
likely influenced by the sequence length as well.
Cleavage of the N-glycosidic bond and loss of the
nucleobase are key elements of the dissociation of
oligodeoxynucleotides, as they induce subsequent
backbone cleavage. Therefore, their role in the dissoci-
ation of platinated oligodeoxynucleotides had to be
elucidated. The product ion spectra of platinated oligo-
nucleotides show weak peaks corresponding to the
negatively charged [G  Pt(NH3)]- and [GG  Pt]-ions
at m/z 360.02 and m/z 493.03, respectively, thus, giving
evidence for cleavage of the N-glycosidic bonds. Fur-
thermore, the observed masses of a-ions generated by
dissociation of platinated oligonucleotides containing
vicinal guanines suggests, that upon backbone dissoci-
ation next to the adduct site, at least one of the two
N-glycosidic bonds remains intact. As shown in Figure
4, the mass of a-ions with both N-glycosidic bonds
remaining intact is one Dalton lower than the mass of
an a-ion with one opened glycosidic bond. The product
ion spectra of all hexanucleotides studied give evidence
for [a  Pt] fragments exhibiting an open glycosidic
bond (data not shown).
Cisplatin is known to form 1,3-intrastand adducts as
well. To obtain further evidence for the cleavage of the
N-glycosidic bond, the adduct of DDP with CGTGCT
was subjected to CID. Besides the expected abundant
peak of the w2-ion, the product ion spectrum shows two
peak clusters at m/z 792.61 and m/z 801.12 (data not
shown). They refer to the [w4  Pt  G] and [w4 
PtNH3  G] fragment ions, and prove that both gua-
nines are still bound to the w4 fragment. The prese-
nce of these fragment ions clearly shows that the
N-glycosidic bond of the second building block is
cleaved. Disruption of the 3=-C–O bond, which leads to
formation of the [w4  Pt] fragment must be the
consequence of prior cleavage of the corresponding
N-glycosidic bond. Additional evidence is provided by
the doubly charged [a4  Pt] fragment with m/z 689.59,
since an intact N-glycosidic bond would lead to a
intact and cleaved N-glycosidic bond, resultingith an
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glycosidic bond is further promoted by formation of a
stabilized furan ring due to additional abstraction of the
4=-H and cleavage of the 3=-C–O bond.
Since a positive charge on the nucleobase weakens
the N-glycosidic bond and accelerates its scission, the
results of the MS/MS experiments met our expectations
[66–69]. However, the presence of the [a4  Pt] frag-
ment clearly shows that the introduction of a positive
charge on the nucleobase by platination does not auto-
matically lead to cleavage of the N-glycosidic bond and
therefore a thorough investigation of fragment ion
formation is of major importance.
Mechanistic Aspects of the Dissociation
Based on the experimental data gained so far, the
following conclusions can be drawn: (1) the binding of
cisplatin influences the dissociation of oligonucleotides,
(2) the 3=-C–O ribose-phosphodiester bond is the pre-Schemeferred cleavage site of platinated oligonucleotides, (3) at
least one N-glycosidic bond at the adduct site is desta-
bilized by the presence of cisplatin and consequently,
cleaved preferentially, and (4) multiple dissociation
pathways are responsible for the formation of the
wx-ion.
Elucidation of the dissociation mechanisms is based
on comparison of the product ion spectra of unplati-
nated and platinated oligodeoxynucleotides, variation
of the base sequences, and the study of methylphospho-
nate analogues. In Schemes 1 and 2 , two fragmentation
mechanisms of platinated oligodeoxynucleotides are
proposed, with CCGGTT as a representative sequence
for all oligodeoxynucleotides studied. In both mecha-
nisms the oxygen atom of the adjacent deprotonated
phosphate group plays a key role, and both pathways
result in formation of the w2-ion (wx-ion) due to back-
bone cleavage on the 3=-side of the GG base pair, thus,
explaining its generally high abundance in the product
ion spectra. The initial steps of the mechanisms are in1
heme
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posed by Wan et al. for unmodified oligonucleotides
[49]. However, in the present study the positive charge
on the GG base pairs is a result of platination and not of
protonation. The latter is believed to be a rather random
event which can take place at any base of the oligonu-
cleotide. On the contrary, the addition of cisplatin
introduces two positive charges on a defined position
within the sequence. Therefore, the proposed mecha-
nisms are not valid for the formation of any fragment
generated upon CID but they are highly specific for the
formation of fragment ions resulting from cleavage in
close vicinity of the cisplatin adduct.
Both mechanisms for platinated oligodeoxynucleoti-
des are related, as both comprise a cascade of 1,2-
eliminations. They are initiated by attack of the 2=-H by
an adjacent negatively charged phosphate oxygen, thus,
resulting in cleavage of the corresponding N-glycosidic
bond due to 1,2-elimination. Electron migration to-
wards the platinum-N7 bond results in compensation of
positive charge that has been introduced by DDP. In a
second step, abstraction of the 4=-H, preferably by
Scattack from the adjacent 5=-phosphate oxygen, leads toa repeated 1,2-elimination and cleavage of the 3=-C–O
bond of the backbone.
In the first step of mechanism M1 (Scheme 1),
abstraction of the 2=-H of the upper guanosine, carried
out by the phosphate group between the two platinum-
bound guanosines, leads to scission of the N-glycosidic
bond. In the second step, the 1,2-elimination reaction,
which is triggered by the 5=-phosphate group leads to
backbone cleavage and generation of the corresponding
[a  G] and [w  Pt  G] fragment ions with the
nucleobase of the upper guanosine still bound to the
released w-ion via the Pt(NH3)2 moiety. In a further
1,2-elimination process the N-glycosidic bond of the
second guanosine is cleaved, thus, releasing the w-ion
along with the Pt(NH3)2G2 moiety. Finally, cleavage of
the 3=-C–O bond results in the 5=-phosphorylated furan
and a w-ion, which is one building block shorter than in
the former intermediate.
In mechanism M2 (Scheme 2), the ribose 2=-position
of the lower guanosine is initially attacked by the
corresponding phosphate oxygen. Scission of the N-
glycosidic bond and 1,2-elimination result in cleavage
2of the 3=-C–O bond and release of the [a  Pt]- and the
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can further proceed via the pathway shown in Scheme 3.
This pathway involves abstraction of the N1-proton
of the released but still platinum-bound guanine by the
phosphate group on the 5=-side of the upper guanosine.
Subsequent electron rearrangement leads to formation
of a platinum-guanine bidentate, while simultaneously
breaking the bond between platinum and N7 of the
upper guanosine. Along this pathway, the a-B and its
complementary w fragment ion are generated. The plau-
sibility of the formation of a platinum-guanine bidentate,
as generated by the mechanism in Scheme 3, has been
demonstrated by Carsey et al. [70], who, based on molec-
ular orbital calculations, showed that DDP can bind equiv-
alently to the N7 and O6 atoms of guanine, thus, suggest-
ing the O6 atom to serve as a coordination center for
platinum as well. Mechanisms M1 and M2 both lead to
w-ions, thus, explaining their enhanced abundance in the
product in spectra of platinated oligonucleotides.
Dissociation of Methylphosphonate-Modified
Oligonucleotides
To provide confirming information about the proposed
dissociation mechanisms experiments on platinated
methylphosphonate oligodeoxynucleotides have been
Scheme 3performed, with CCGGTT as a representative nucleotidesequence. The sites of backbone modification are indi-
cated in Figure 5. The introduction of methylphosphonate-
modifications within the oligonucleotide backbone dis-
ables deprotonation at these positions, thus, masking
potentially reactive sites. If a dissociation mechanism
involves a certain phosphate group, substitution by a
methylphosphonate will locally inhibit the correspond-
ing reaction step, thus, blocking further degradation.
The effect of selected modifications on the dissociation
of the oligonucleotide will finally be observable as an
alteration in the fragment ion pattern.
As demonstrated previously, the simultaneous ap-
pearance of a- and a-B-ions and the greatly enhanced
abundance of the wx-ion suggest, that multiple dissoci-
ation pathways apply to the dissociation of platinated
oligodeoxynucleotides. The assumption of multiple
pathways is further supported by the observation that
the wx-ion intensity remains quite unaffected by the
introduction of single methylphosphonate-modifications at
various positions within the backbone (spectra not
shown). An almost complete exchange of the phosphate
groups with methylphosphonates is required to inhibit
the formation of the prominent wx-ion. As shown in
Figure 5. Methylphosphonate-modified hexamers. The black
marker indicates the site of the modification.
of th
800 NYAKAS ET AL. J Am Soc Mass Spectrom 2009, 20, 792–804Figure 6b, two unmodified phosphate groups in mech-
anistically relevant positions are sufficient to obtain
wx-ions of significant abundance. Also, secondary frag-
ment ions, such as the [w2-w1]-ion in the product ion
spectrum of CxCxGGTxT, are considered to derive from
the w2-ion.
The fact that at least two unmodified phosphate
groups are required to generate the wx-ion, proves that
both groups are involved in the mechanism thus, pro-
viding evidence for the proposed multi-step mecha-
nisms. The strong peak of the w1-ion in Figure 6a can be
ascribed to the attack of the 4=-H of the neighboring
sugar ring by N1 of the terminal thymine. This mecha-
nism is based on previous studies of methylphosphonate-
modified oligonucleotides, which have been performed
without the addition of cisplatin, though [71]. Since the
attack does not occur in close proximity to the DDP
adduct, such a mechanism is feasible.
Comparing the product ion spectra of unplatinated
and platinated methylphosphonate-oligonucleotides it
is generally striking that the number of fragment ion
peaks is drastically decreased after addition of DDP,
even more than in the case of unplatinated native
oligonucleotides. Hence, fragmentation next to the GG
base pair is even more favored for methylphosphonate-
modified sequences. The intensity of the a-G- and [a 
Pt]-ions in the product ion spectra of methylphosphonate-
oligodeoxynucleotides changed significantly if the
position of a single methylphosphonate-modification
was shifted from the 5=-side of the GG base pair to the
3=-side (MP-1 to MP-3 in Figure 5). Formation of the
a4-G and [a4  Pt] fragment ion is almost completely
inhibited for MP-3 and the abundance of the a3-G-ion is
significantly lowered in the product ion spectrum of
MP-2, thus, reflecting the highly retarding effect exerted
by the modification. However, the formation of both
fragments is only weakly affected if phosphate groups
at different positions are replaced by methylphospho-
Figure 6. Product ion spectra of methylphosph
unmodified phosphate groups. As far as two ph
remain unmodified, the w2-ion is observed in hig
fragment ions is observed. (“x” denotes the sitenates, as revealed by CID of MP-4 to MP-7 (data notshown). These observations support the proposed
mechanisms, as they point out the requirement of an
unblocked 3=-phosphate group adjacent to a platinated
guanosine for the initial cleavage step to take place.
In the product ion spectrum of MP-2, a4-G and [a4 
Pt] were observed with reduced abundance only. Ac-
cording to mechanism M2, the initial step, which in-
volves attack of the 3=-phosphate can take place. The
reduced abundance of the fragment ions may be ex-
plained by the presence of the methylphosphonate
in-between the two guanines, which blocks further
degradation according to mechanisms M2. Similar ob-
servations were made for the reduced formation of a3-G
from MP-1. The fact that these fragment ions are still
observable despite formal blocking of the second reac-
tion step gives evidence for different phosphate groups
being able to carry out this dissociation pathway. Com-
paring these results with the proposed mechanisms
there is an apparent coincidence regarding the first
dissociation step. If the phosphate group carrying out
the first attack is inactivated by a methyl group, the
whole dissociation pathway is inhibited. However, mask-
ing of the phosphate oxygen atom, which acts in the
second or third step of the reaction, hasmuch less effect on
the formation of the corresponding fragment. This obser-
vation suggests that once the fragmentation is initiated, a
phosphate group in a remote position from the cleavage
site is able to abstract the proton as well, though there is a
clear preference for an attack from the adjacent phosphate
group. This finding is consistent with the fact that the
formation of the w2-ion is only inhibited if less than two
phosphate oxygen atoms remain unmodified.
Binding of Cisplatin to Oligoribonucleotides
(RNA)
GG specific cleavage was found for complexes of DDP
e-modified CCGGTT  Pt bearing one and two
ate groups in mechanistically relevant position
ndance. Additionally, an overall decrease of the
e modification).onat
osph
h abuwith DNA. To investigate whether the tendency for
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cleotides, the RNA analogues of all three hexamers
(CGGCUU, CCGGUU, and CCUGGU) have been sub-
jected to CID. Unlike DNA, which predominantly dis-
sociates into a-B- and w-ions, RNA tends to form c- and
y-ions upon CID. Therefore, an extraordinary abun-
dance of w-ions generated by dissociation of RNA
adducts would be an unambiguous evidence for the
influence of cisplatin on the dissociation of RNA.
In Figure 7 the spectra of unplatinated and plati-
nated hexaribonucleotides are displayed. As expected
in reference to previous studies, the spectra of all three
unplatinated oligoribonucleotides (Figure 7a, c, and e)
show the complete series of c- and y-ions. Additionally,
w-ions are generated with lower abundance. Two quite
strong peaks of doubly charged ions with m/z 565.40
and m/z 578.73 refer to the loss of one guanine or
cytosine, respectively. Overall, there are no peaks of
extraordinary abundance, thus, indicating a balanced
fragmentation behavior in absence of a favored cleav-
age site within the sequence. In contrast, the spectra of
the corresponding cisplatin adducts all exhibit w-ion
Figure 7. Product ion spectra of unplatinate
increase of the wx-ion abundance is observed after thpeaks of increased intensity. This fact is represented by
the w3-ion peak (m/z 466.55) in the product ion spec-
trum of CGGCUU  Pt (Figure 7b), the peaks of the
singly and doubly charged w2-ions (m/z 629.04 and m/z
314.04, respectively) from CCGGUU  Pt (Figure 7d),
and finally, the all dominating w1-ion (m/z 323.03) from
CCUGGU  Pt (Figure 7f). These w-ions are generated
by cleavage of the 3=-C–O bond adjacent to the vicinal
guanines, and are referred to as “wx-ions.” wx-Ions
constitute the peaks of highest intensity in the product
ion spectra of the hexaribonucleotide-cisplatin adducts.
Considering the fact that y-ions are the predominant
3=-terminal fragments of native RNA, the presence of
highly abundant wx-ions gives evidence for the altered
dissociation due to adduct formation with cisplatin.
Since the length of the wx-ions varies with respect to a
shift of the GG-DDP moiety, they can serve as an
indicator for the position of the GG base pairs within
the ribonucleotide sequences.
The preferred formation of [a  Pt]-ions, which was
observed for DNA-cisplatin adducts, is much less pro-
nounced in combination with RNA. Except for [a4  Pt]
d platinated RNA-hexamers. As for DNA and an
e addition of DDP.
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generated by sequence-specific backbone cleavage after
the GG base pair, namely [a3  Pt] (m/z 553.05) from
CGGCUU Pt, [a4 Pt] (m/z 705.56) from CCGGUU
Pt, and [a5  Pt] (m/z 859.10) from CCUGGU  Pt,
which all appear in rather low abundance. These [an x 
Pt]-ions are complementary to the wx-ions, thus, are
indicative for the position of the GG base pair as well.
Among the 5=-terminal fragments, the [c  Pt]-ions
constitute the most prevalently formed cleavage prod-
ucts of platinated RNA (except for the [anx  Pt]-ion).
The relative peak intensities as well as the total number
of platinated ions are the largest for the c-series. There-
fore, the conclusion can be drawn that platination does
not alter the entire fragmentation of oligoribonucleo-
tides but it does have a strong effect on the dissociation
in close vicinity of the GG base pair.
Formation of the 3=-terminal y-ions is only weakly
affected by platination and there is no evidence for any
platinated y-ion of considerable abundance. This find-
ing is consistent with the results obtained from the
investigation of oligodeoxynucleotides. [y  Pt]-ions
would derive from bond cleavage on the 5=-side of the
GG-cisplatin moiety, and experiments on DNA ana-
logues already revealed a clearly reduced fragmenta-
tion on this side of the GG base pair as a result of
cisplatin addition. Also, the tendency for reduced gen-
eration of cleavage products on the 5=-side of the vicinal
guanines is as noticeable for RNA as it is for the DNA
analogues studied previously. Due to the position of
GG this effect is less pronounced for CGGCUU  Pt
and CCGGUU  Pt than for CCUGGU  Pt. For
platinated CGGCUU and CCGGUU, the peak of the
singly charged c1-ion (m/z 304.04) and the peak of [a2 
C] (m/z 418.08, exclusively in the spectrum of CCGGUU 
Pt) are the only representatives of fragment ions that
derive from the 5=-side of GG. Even CCUGGU  Pt,
with the guanines shifted toward the 3=-end, shows
strong suppression of fragment ion generation on the
5=-side of GG, with c1 (m/z 304.0), c3 (m/z 457.05), and y3
(m/z 466.06) as the only observable fragments from this
part of the sequence. No further fragments belonging to
the y- or w-ion series in unplatinated or platinated form
were observed. The overall reduction of fragmentation
on the 5=-side of the GG base pair was found to be less
pronounced for platinated RNA than for platinated
DNA.
As mentioned previously, a distinct fragmentation
on the 3=-side of GG resulting in y-, w-, [c  Pt]-, and
[an x  Pt]-ions, was observed. For CGGCUU and
CCGGUU the abundance of the w1- (m/z 323.04), w2-
(m/z 314.04, 629.04), and w3-ion (m/z 466.55) increased
after addition of cisplatin. At first sight the w1-ion
abundance in the product ion spectrum of CCGGUU 
Pt even seems to exceed the signal of the w2-ion. After
combining the intensities of the singly and doubly
charged species (m/z 314.04, 629.04), it becomes clear
that w2-ion formation clearly outweighs the relative
intensity of the w1-ion. The observation of increasedw1-ion generation is in contrast to the behavior of DNA,
which was found to point into the opposite direction.
w1-Ions represent by far the most abundant fragment
ions in the product ion spectra of unplatinated DNA
(data not shown). After formation of the GG-DDP
adducts in CGGCTT and CCGGTT, the relative inten-
sity of the w1-ion decreased to about 20-30% of the
abundance of the corresponding wx-ion. In the case of
CCTGGT  Pt, this effect cannot be investigated since
the w1-ion also constitutes the wx-ion and hence, is the
most intensive fragment anyway. This difference be-
tween RNA and DNA can most likely be attributed to
the variation of the 2=-substituent.
Another remarkable characteristic of the product ion
spectra of platinated RNA is the increased occurrence of
unplatinated a-B-ions, such as a3-G from CGGCUU 
Pt and CCGGUU  Pt, a4-G from CCUGGU  Pt, and
a2-G from CGGCUU  Pt, in comparison to unpla-
tinated oligoribonucleotides. They are generated by
backbone cleavage in-between or 3=-adjacent to the GG
base pair in combination with cleavage of the N-
glycosidic bond of one of the guanines. This indicates
that platinated RNA is following the same fragmenta-
tion mechanism as proposed for their DNA analogues.
In general, the increased formation of these a-B-ions
further reveals the altered gas-phase dissociation of
RNA due to the presence of cisplatin, since these
fragments are highly atypical fragments with respect to
previous studies.
Comparing the product ion spectra of platinated
RNA and DNA, the complexity of the spectra is in-
creased for RNA, while for DNA a rather simple picture
with reduced fragment ion diversity is obtained. This is
basically due to the additionally generated c-, [c  Pt]-,
and y-ions in the spectra of platinated RNA, which do
not occur in the spectra of the platinated DNA.
Experimental data revealed that the binding of cis-
platin forces the dissociation of both types of oligonu-
cleotides into a similar direction, despite the fact that in
their unplatinated form they exhibit intrinsically differ-
ent fragmentation pathways.
Conclusion
The investigation of the gas-phase behavior of plati-
nated oligonucleotides has shown that their fragmenta-
tion is strongly altered in comparison to unmodified
oligonucleotides. For oligodeoxynucleotides, two disso-
ciation mechanisms are responsible for the generation
of the all-dominating wx-ion and the lack of a comple-
mentary-ion of equivalent abundance. The initial step of
the dissociation cascade was found to originate from
one specific phosphate group. Attack by the phosphate
oxygen atom on the 3=-side of the cleavage site triggers
the cleavage of the N-glycosidic bond. Subsequent
1,2-elimination from the ribose leads to backbone cleav-
age and the formation of characteristic [a  Pt]- and
a-B-ions. Further degradation involves repeated 1,2-
elimination reactions, which preferentially arise from
803J Am Soc Mass Spectrom 2009, 20, 792–804 DISSOCIATION OF PLATINATED OLIGONUCLEOTIDESthe phosphate groups on the 5=-side. However, studies
on methylphosphonate-modified oligonucleotides de-
monstrated that phosphate groups at different positions
within the backbone can be involved in the second and
third dissociation step as well, thus, providing alterna-
tive routes to the final degradation products and de-
creasing the yield of a-ions. Experiments on oligoribo-
nucleotides revealed that the typical dissociation
pathway of RNA is altered due to platination. While
unplatinated RNA preferentially generates c and y
fragments, there is an increased formation of w-, a-B-,
and [a  Pt]-ions from platinated RNA, due to back-
bone cleavage in proximity of the adduct site.
Acknowledgments
The authors gratefully acknowledge financial support of this work
by the Swiss National Science Foundation (grant no. 200020-
111877).
References
1. Rosenberg, B.; Van Camp, L.; Krigas, T. Inhibition of Cell Division in
Escherichia coli by Electrolysis Products from a Platinum Electrode.
Nature 1965, 205(4972), 698–699.
2. Khan, A.; Hill, J. M. Immunosuppression with Cis-platinum (II)
Diamminodichloride—Effect on Antibody Plaque-Forming Spleen
Cells. Infect. Immun. 1971, 4(3), 320–321.
3. Jamieson, E. R.; Lippard, S. J. Structure, Recognition, and Processing of
Cisplatin-DNA Adducts. Chem. Rev. 1999, 99(9), 2467–2498.
4. Reedijk, J. New Clues for Platinum Antitumor Chemistry: Kinetically
Controlled Metal Binding to DNA. Proc. Natl. Acad. Sci. U.S.A. 2003,
100(7), 3611–3616.
5. Rosenberg, B. Noble Metal Complexes in Cancer Chemotherapy. Adv.
Exp. Med. Biol. 1977, 91, 129–150.
6. Wong, E.; Giandomenico, C. M. Current Status of Platinum-Based
Antitumor Drugs. Chem. Rev. 1999, 99(9), 2451–2466.
7. Adler, H. I.; Hardigree, A. A. Postirradiation Growth Division and
Recovery in Bacteria. Radiat. Res. 1965, 25(1), 92–102.
8. Akaboshi, M.; Kawai, K.; Maki, H.; Akuta, K.; Ujeno, Y.; Miyahara, T.
The Number of Platinum Atoms Binding to DNA, RNA and Protein
Molecules of HELA-Cells treated with Cisplatin at Its Mean Lethal
Concentration. Jpn J. Cancer Res. 1992, 83(5), 522–526.
9. Haraguchi, H. Metallomics as Integrated Biometal Science. J. Anal. At.
Spectrom. 2004, 19(1), 5–14.
10. Harder, H. C. Inhibitory Effects of Anti-Tumor Platinum Compounds
on DNA, RNA, and Protein Syntheses in Mammalian Cells In Vitro. Int.
J. Cancer 1970, 6(2), 207–216.
11. Howle, J. A.; Gale, G. R. Cis-Dichlorodiammineplatinum (II): Persistent
and Selective Inhibition of Deoxyribonucleic Acid Synthesis In Vivo.
Biochem. Pharmacol. 1970, 19(10), 2757–2762.
12. Pascoe, J. M.; Roberts, J. J. Interactions Between Mammalian-Cell DNA
and Inorganic Platinum Compounds. 1. DNA Interstrand Crosslinking
and Cytotoxic Properties of Platinum(II) Compounds. Biochem. Pharma-
col. 1974, 23(9), 1345–1357.
13. Reslova, S. The Induction of Lysogenic Strains of Escherichia coli by
Cis-Dichlorodiammineplatinum (II). Chem. Biol. Interact. 1971, 4(1),
66–70.
14. Rosenkranz, H. S.; Garro, A. J.; Levy, J. A.; Carr, H. S. Studies with
Hydroxyurea. I. The Reversible Inhibition of Bacterial DNA Synthesis
and the Effect of Hydroxyurea on the Bactericidal Action of Streptomy-
cin. Biochim. Biophys. Acta 1966, 114(3), 501–515.
15. Speelmans, G.; Sips, W.; Grisel, R. J. H.; Staffhorst, R.; Fichtinger-
Schepman, A. M. J.; Reedijk, J.; de Kruijff, B. The Interaction of the
Anti-Cancer Drug Cisplatin with Phospholipids is Specific for Nega-
tively Charged Phospholipids and Takes Place at Low Chloride Ion
Concentration. Biochim. Biophys. Acta Biomembranes 1996, 1283(1), 60–66.
16. Speelmans, G.; Staffhorst, R.; Versluis, K.; Reedijk, J.; de Kruijff, B.
Cisplatin Complexes with Phosphatidylserine in membranes. Biochem-
istry 1997, 36(34), 10545–10550.
17. Witkin, E. M. The Radiation Sensitivity of Escherichia coli B: a Hypoth-
esis relating Filament Formation and Prophage Induction. Proc. Natl.
Acad. Sci. U.S.A. 1967, 57(5), 1275–1279.
18. Jansen, B. A. J.; Brouwer, J.; Reedijk, J. Glutathione Induces Cellular
Resistance Against Cationic Dinuclear Platinum Anticancer Drugs.
J. Inorg. Biochem. 2002, 89(3/4), 197–202.19. Ghezzi, A.; Aceto, M.; Cassino, C.; Gabano, E.; Osella, D. Uptake of
Antitumor Platinum(II)-Complexes by Cancer Cells, Assayed by Induc-tively Coupled Plasma Mass Spectrometry (ICP-MS). J. Inorg. Biochem.
2004, 98(1), 73–78.
20. Wang, D.; Lippard, S. J. Cellular Processing of Platinum Anticancer
Drugs. Nat. Rev. Drug Discov. 2005, 4(4), 307–320.
21. Fichtinger-Schepman, A. M. J.; Vanderveer, J. L.; Denhartog, J. H. J.;
Lohman, P. H. M.; Reedijk, J. Adducts of the Antitumor Drug Cis-
Diamminedichloroplatinum(II) with DNA—Formation, Identification,
and Quantitation. Biochemistry 1985, 24(3), 707–713.
22. Bosl, G. J.; Motzer, R. J. Testicular Germ-Cell Cancer. New Engl. J. Med.
1997, 337(4), 242–254.
23. McGowan, G.; Parsons, S.; Sadler, P. J. Contrasting Chemistry of Cis-
and Trans-Platinum(II) Diamine Anticancer Compounds: Hydrolysis
Studies of Picoline Complexes. Inorg. Chem. 2005, 44(21), 7459–7467.
24. Eastman, A. Reevaluation of Interaction of Cis-Dichloro(Ethylenediamine)
Platinum(II) with DNA. Biochemistry 1986, 25(13), 3912–3915.
25. Fichtinger-Schepman, A. M. J.; Vanoosterom, A. T.; Lohman, P. H. M.;
Berends, F. Cis-Diamminedichloroplatinum(II)-Induced DNA Adducts
in peripheral Leukocytes from 7 Cancer Patients—Quantitative Immu-
nochemical Detection of the Adduct Induction and Removal after a
Single Dose of Cis-Diamminedichloroplatinum(II). Cancer Res. 1987,
47(11), 3000–3004.
26. Poirier,M. C.; Reed, E.; Zwelling, L. A.; Ozols, R. F.; Litterst, C. L.; Yuspa, S. H.
Polyclonal Antibodies to Quantitate Cis-Diamminedichloroplatinum(II)-DNA
Adducts in Cancer Patients andAnima -Models.Environ. Health Perspect. 1985,
62(10), 89–94.
27. Reed, E.; Ozols, R. F.; Tarone, R.; Yuspa, S. H.; Poirier, M. C. Platinum-
DNA Adducts in Leukocyte DNA Correlate with Disease Response in
Ovarian-Cancer Patients Receiving Platinum-Based Chemotherapy.
Proc. Natl. Acad. Sci. U.S.A. 1987, 84(14), 5024–5028.
28. Reed, E.; Yuspa, S. H.; Zwelling, L. A.; Ozols, R. F.; Poirier, M. C.
Quantitation of Cis-Diamminedichloroplatinum-II (Cisplatin)-DNA-
Intrastrand Adducts in Testicular and Ovarian-Cancer Patients Receiv-
ing Cisplatin Chemotherapy. J. Clin. Investig. 1986, 77(2), 545–550.
29. Admiraal, G.; Vanderveer, J. L.; Degraaff, R. A. G.; Denhartog, J. H. J.; Reedijk,
J. IntrastrandBis(Guanine)Chelation ofD(CpGpG) toCisplatinum—anX-Ray
Single-Crystal Structure Analysis. J. Am. Chem. Soc. 1987, 109(2), 592–594.
30. Yang, D. Z.; Vanboom, S.; Reedijk, J.; Vanboom, J. H.; Wang, A. H. J.
Structure and Isomerization of an Intrastrand Cisplatin-Cross-Linked
Octamer DNA Duplex by NMR Analysis. Biochemistry 1995, 34(39),
12912–12920.
31. Harder, H. C.; Smith, R. G.; Leroy, A. F. Template Primer Inactivation
by Cis-Dichlorodiamine and Trans-Dichlorodiamine Platinum for Hu-
man DNA-Polymerase , , and Rauscher Murine Leukemia-Virus
Reverse-Transcriptase, as a Mechanism of Cytotoxicity. Cancer Res.
1976, 36(10), 3821–3829.
32. Hoffmann, J. S.; Johnson, N. P.; Villani, G. Conversion of Monofunc-
tional DNA Adducts of Cis-Diamminedichloroplatinum(II) to Bifunc-
tional Lesions—Effect on the In Vitro Replication of Single-Stranded-
DNA by Escherichia coli DNA-Polymerase-I and Eukaryotic DNA
Polymerases-. J. Biol. Chem. 1989, 264(25), 15130–15135.
33. Johnson, N. P.; Hoeschele, J. D.; Kuemmerle, N. B.; Masker, W. E.; Rahn,
R. O. Effects of Platinum Anti-Tumor Agents and Pyrimidine Dimers on
In Vitro Replication of T7-DNA. Chem. Biol. Interact. 1978, 23(2), 267–271.
34. Pinto, A. L.; Lippard, S. J. Sequence-Dependent Termination of In Vitro
DNA-Synthesis by Cis-Diamminedichloroplatinum(II) and Trans-
Diamminedichloroplatinum(II). Proc. Natl. Acad. Sci. U.S.A. 1985, 82(14),
4616–4619.
35. Villani, G.; Hubscher, U.; Butour, J. L. Sites of Termination of In Vitro
DNA-Synthesis on Cis-Diamminedichloroplatinum(Ii) Treated Single-
Stranded-DNA—a Comparison Between Escherichia coliDNA-Polymerase-I
and Eukaryotic DNA Polymerases-. Nucleic Acids Res. 1988, 16(10),
4407–4418.
36. Corda, Y.; Job, C.; Anin, M. F.; Leng, M.; Job, D. Transcription by Eukaryotic
and Prokaryotic RNA-Polymerases of DNAModified at a D(GG) or a D(AG)
Site by the Antitumor Drug Cis-Diamminedichloroplatinum(II). Biochemistry
1991, 30(1), 222–230.
37. Cullinane, C.; Mazur, S. J.; Essigmann, J. M.; Phillips, D. R.; Bohr, V. A.
Inhibition of RNA Polymerase II Transcription in Human Cell Extracts
by Cisplatin DNA Damage. Biochemistry 1999, 38(19), 6204–6212.
38. Lemaire, M. A.; Schwartz, A.; Rahmouni, A. R.; Leng, M. Interstrand
Cross-Links are Preferentially Formed at the D(GC) Sites in the Reaction
Between Cis-Diamminedichloroplatinum(Ii) and DNA. Proc. Natl. Acad.
Sci. U.S.A. 1991, 88(5), 1982–1985.
39. Sorenson, C. M.; Eastman, A. Mechanism of Cis-Diamminedichloroplatinum
(II)-inducedCytotoxicity—Role of G2Arrest andDNADouble-Strand Breaks.
Cancer Res. 1988, 48(16), 4484–4488.
40. Gonnet, F.; Kocher, F.; Blais, J. C.; Bolbach, G.; Tabet, J. C.; Chottard, J. C.
Kinetic Analysis of the Reaction Between d(TTGGCCAA) and
[Pt(NH3)(3)(H2O)](2) by Enzymatic Degradation of the Products and
ESI and MALDI Mass Spectrometries. J. Mass Spectrom. 1996, 31(7),
802–809.
41. Marchan, V.; Moreno, V.; Pedroso, E.; Grandas, A. Towards a Better
Understanding of the Cisplatin Mode of Action. Chem. A Eur. J. 2001,
7(4), 808–815.
42. Meczes, E. L.; Azim-Araghi, A.; Ottley, C. J.; Pearson, D. G.; Tilby, M. J.
Specific Adducts Recognized by a Monoclonal Antibody Against
Cisplatin-Modified DNA. Biochem. Pharmacol. 2005, 70(12), 1717–1725.43. Troujman, H.; Chottard, J. C. Comparison between HPLC and Capillary
Electrophoresis for the Separation and Identification of the Platination
804 NYAKAS ET AL. J Am Soc Mass Spectrom 2009, 20, 792–804Products of Oligonucleotides with Cis-[Pt(NH3)(2)(H2O)(2)](2). Anal.
Biochem. 1997, 252(1), 177–185.
44. Grotjahn, L.; Frank, R.; Blocker, H. Ultrafast Sequencing of Oligode-
oxyribonucleotides by FAB-Mass Spectrometry. Nucleic Acids Res. 1982,
10(15), 4671–4678.
45. Sindona, G.; Uccella, N.; Weclawek, K. Structure Determination of
Isomeric Oligodeoxynucleotide Salts by Fast-Atom-Bombardment
Mass-Spectrometry. J. Chem. Res. S 1982, 184–185.
46. Panico, M.; Sindona, G.; Uccella, N. Bioorganic Applications of Mass
Spectrometry. 3. Fast-Atom-Bombardment-Induced Zwitterionic Oligo-
nucleotide Quasimolecular Ions Sequenced by MS/MS. J. Am. Chem.
Soc. 1983, 105(17), 5607–5610.
47. Cerny, R. L.; Gross, M. L.; Grotjahn, L. Fast-Atom-Bombardment
Combined with Tandem Mass-Spectrometry for the Study of Dinucle-
otides. Anal. Biochem. 1986, 156(2), 424–435.
48. Wang, Z.; Wan, K. X.; Ramanathan, R.; Taylor, J. S.; Gross, M. L.
Structure and Fragmentation Mechanisms of Isomeric T-Rich Oligode-
oxynucleotides: A Comparison of Four Tandem Mass Spectrometric
Methods. J. Am. Soc. Mass Spectrom. 1998, 9(7), 683–691.
49. Wan, K. X.; Gross, J.; Hillenkamp, F.; Gross, M. L. Fragmentation
Mechanisms of Oligodeoxynucleotides Studied by H/D Exchange and
Electrospray Ionization Tandem Mass Spectrometry. J. Am. Soc. Mass
Spectrom. 2001, 12(2), 193–205.
50. Wan, K. X.; Gross, M. L. Fragmentation Mechanisms of Oligode-
oxynucleotides: Effects of Replacing Phosphates with Methylphospho-
nates and Thymines with Other Bases in T-Rich Sequences. J. Am. Soc.
Mass Spectrom. 2001, 12(5), 580–589.
51. Cerny, R. L.; Tomer, K. B.; Gross, M. L.; Grotjahn, L. Fast-Atom-
Bombardment Combined with Tandem Mass-Spectrometry for Deter-
mining Structures of Small Oligonucleotides. Anal. Biochem. 1987,
165(1), 175–182.
52. Schürch, S.; Bernal-Mendez, E.; Leumann, C. J. Electrospray Tandem
Mass Spectrometry of Mixed-Sequence RNA/DNA Oligonucleotides.
J. Am. Soc. Mass Spectrom. 2002, 13(8), 936–945.
53. Tromp, J. M.; Schürch, S. Gas-Phase Dissociation of Oligoribonucleo-
tides and Their Analogs Studied by Electrospray Ionization Tandem
Mass Spectrometry. J. Am. Soc. Mass Spectrom. 2005, 16(8), 1262–1268.
54. Andersen, T. E.; Kirpekar, F.; Haselmann, K. F. RNA Fragmentation in
MALDI Mass Spectrometry Studied by H/D-Exchange: Mechanisms of
General Applicability to Nucleic Acids. J. Am. Soc. Mass Spectrom. 2006,
17(10), 1353–1368.
55. Puzo, G.; Prome, J. C.; Macquet, J. P.; Lewis, I. A. S. Fast Atom
Bombardment Mass-Spectra of the Bis-Guanosine Adduct with Cispla-
tin. Biomed. Mass Spectrom. 1982, 9(12), 552–556.
56. Roos, I. A. G.; Thomson, A. J.; Eagles, J. Mass-Spectrometric Studies of
Interaction of Platinum Complexes with Nucleoside Analogs. Chem.
Biol. Interact. 1974, 8(6), 421–427.
57. Hunt, D. F.; Hignite, C. E.; Biemann, K. Structure Elucidation of
Dinucleotides by Mass Spectrometry. Biochem. Biophys. Res. Commun.
1968, 33(3), 378–383.58. McCloskey, J. A.; Lawson, A. M.; Tsuboyama, K.; Krueger, P. M.;
Stillwell, R. N. Mass Spectrometry of Nucleic Acid Components.
Trimethylsilyl Derivatives of Nucleotides, Nucleosides, and Bases.
J. Am. Chem. Soc. 1968, 90(15), 4182–4184.
59. Macquet, J. P.; Jankowski, K.; Butour, J. L. Mass-Spectrometry Study of
DNA-Cisplatin Complexes—Pertubation of Guanine-Cytosine Base
Pairs. Biochem. Biophys. Res. Commun. 1980, 92(1), 68–74.
60. Claereboudt, J.; Despiegeleer, B.; Debruijn, E. A.; Gijbels, R.; Claeys, M.
Structural Characterizations of Cisplatin Analogs by Fast Atom Bom-
bardment (FAB) and Laser Microprobe Mass-Spectrometry (LAMMA).
J. Pharm. Biomed. Anal. 1989, 7(12), 1599–1610.
61. Martin, L. B.; Schreiner, A. F.; Vanbreemen, R. B. Characterization of
Cisplatin Adducts of Oligonucleotides by Fast-Atom-Bombardment
Mass-Spectrometry. Anal. Biochem. 1991, 193(1), 6–15.
62. Costello, C. E.; Comess, K. M.; Plaziak, A. S.; Bancroft, D. P.; Lippard,
S. J. Fast-Atom-Bombardment and High-Performance Tandem Mass-
Spectrometry Of Platinum(II) Oligodeoxyribonucleotide Fragments. Int.
J. Mass Spectrom. Ion Processes 1992, 122, 255–279.
63. Baik, M. H.; Friesner, R. A.; Lippard, S. J. Theoretical Study on the
Stability of N-Glycosyl Bonds: Why Does N7-Platination not Promote
Depurination? J. Am. Chem. Soc. 2002, 124(16), 4495–4503.
64. Iannitti-Tito, P.; Weimann, A.; Wickham, G.; Sheil, M. M. Structural
Analysis of Drug-DNA Adducts by Tandem Mass Spectrometry. Ana-
lyst 2000, 125(4), 627–633.
65. Zhang, Q. R.; Yu, E. T.; Kellersberger, K. A.; Crosland, E.; Fabris, D.
Toward Building a Database of Bifunctional Probes for the MS3D
Investigation of Nucleic Acids Structures. J. Am. Soc. Mass Spectrom.
2006, 17(11), 1570–1581.
66. Iannitti, P.; Sheil, M. M.; Wickham, G. High Sensitivity and Fragmen-
tation Specificity in the Analysis of Drug-DNAAdducts by Electrospray
Tandem Mass Spectrometry. J. Am. Chem. Soc. 1997, 119(6), 1490–1491.
67. Barry, J. P.; Vouros, P.; Vanschepdael, A.; Law, S. J. Mass and Sequence
Verification of Modified Oligonucleotides Using Electrospray Tandem
Mass Spectrometry. J. Mass Spectrom. 1995, 30(7), 993–1006.
68. Marzilli, L. A.; Barry, J. P.; Sells, T.; Law, S. J.; Vouros, P.; Harsch, A.
Oligonucleotide Sequencing Using Guanine-Specific Methylation and
Electrospray Ionization Ion Trap Mass Spectrometry. J. Mass Spectrom.
1999, 34(4), 276–280.
69. Kirpekar, F.; Nordhoff, E.; Kristiansen, K.; Roepstorff, P.; Hahner, S.;
Hillenkamp, F. 7-Deaza Purine Bases Offer a Higher Ion Stability in the
Analysis of DNA by Matrix-Assisted Laser Desorption/Iionization
Mass Spectrometry. Rapid Commun. Mass Spectrom. 1995, 9(6), 525–531.
70. Carsey, T. P.; Boudreaux, E. A. The Electronic Structure of Platinum-
Guanine Complexes. Chem. Biol. Interact. 1980, 30(2), 189–201.
71. Monn, S. T. M.; Schürch, S. New Aspects of the Fragmentation Mech-
anisms of Unmodified and Methylphosphonate-Modified Oligonucleo-
tides. J. Am. Soc. Mass Spectrom. 2007, 18(6), 984–990.
